Page 36 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $5.25
52wk Low $0.46 Kiora Pharmaceuticals, Inc. KPRX $0.56
332 Encinitas Boulevard
Encinitas, CA 92024

(USD - in millions) www.kiorapharma.com
Market Cap 15.1
Enterprise 12.7
Basic Shares Out. 26.26 COMPANY OVERVIEW
Float 19.58
Institutional Holdings 2.01% Detailed Analysis:Channelchek.com
Short Interest 0.05
Avg. 90-Day Volume 1.68 Kiora Pharmaceuticals is a clinical-stage biotechnology company
developing and commercializing products for the treatment of orphan
retinal diseases. KIO-301 is being developed for the treatment of
retinitis pigmentosa, choroideremia, and Stargardt disease. It is a
EPS Data molecular photoswitch that has the potential to restore vision in
patients with inherited and/or age-related retinal degeneration. KIO-104
2021 2022 2023 is being developed for the treatment of posterior non-infectious uveitis.
CQ1 (14.80) (10.80) (1.00) It is a next-generation, non-steroidal, immuno-modulatory, and small
CQ2 (14.00) (7.20) (0.79) molecule inhibitor of dihydroorotate dehydrogenase.

CQ3 (11.60) (6.03) (0.89)
CQ4 (31.20) (1.76) (0.39)
CY (70.80) (18.55) (2.69) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.79
ROE (ttm) -142.88
Debt-to-Total Cap. (mrq) 1.72
Fiscal Year End 31-Dec
332 Encinitas Encinitas CA 92024

Key Executives
CEO: Strem, Brian
CFO: Tosca, Melissa
COO: Sperl, Stefan
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures